"The design of NKTR-214 provides dramatic efficacy in an aggressive and resistant preclinical model of melanoma, despite dosing 10-fold less cytokine at a significantly lower dosing frequency as compared to standard aldesleukin dosing," said
NKTR-214 is a novel immunocytokine therapy that is engineered using Nektar's polymer conjugate technology to selectively target the beneficial IL-2 receptor complex. NKTR-214 maintains high affinity for the IL-2 receptor subunit beta, which activates tumor-killing T-cells within the tumor microenvironment. At the same time, NKTR-214 exhibits up to 100-fold reduced affinity to the IL-2 receptor subunit alpha-beta, which is designed to minimize the immunosuppressive effects that normally limit the efficacy of standard aldesleukin. In the preclinical data presented at ASCO, NKTR-214 exhibits efficacy and tolerability that is superior to the clinically approved cytokine aldesleukin (Proleukin®). NKTR-214 was as efficacious as aldesleukin, even when NKTR-214 was dosed with 20-fold less total cytokine or dosed only once every fourteen days. NKTR-214 is currently undergoing further pre-clinical IND-enabling toxicological and efficacy studies.
NKTR-214 Preclinical Data Presentation
Abstract Title: "An engineered immunotherapy (NKTR-214) with altered selectivity towards the IL-2 receptor: Efficacy and tolerability in a murine tumor model", Charych et al.
- Abstract Number: 3060
- Session Title/Track: Developmental Therapies - Immunotherapy
- Date:
June 3, 2013 ,8:00 a.m. —11:45 a.m. Central Time - Location: S Hall A2
About Nektar
Nektar's technology has enabled eight approved products in the U.S. or
Nektar is headquartered in
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the therapeutic potential of NKTR-214 and the value and potential of our technology and drug candidates in our research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking
statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) positive preclinical efficacy findings, such as those for NKTR-214 reported in this press release, are subject to inherent scientific and medical uncertainties typical for this early stage of drug development and may not be confirmed in subsequent preclinical studies or in clinical trials, if any; (ii) NKTR-214 is in early stage research and there are a number of hurdles,
including the successful completion of preclinical toxicology studies, prior to the potential commencement of clinical studies for NKTR-214; (iii) our drug candidates and those of our collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in previous preclinical and clinical studies; (iv) the timing of the commencement or end of clinical trials and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining
regulatory approval in one or more important markets; (v) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of our technology platform to potential new drug candidates (such as NKTR-214) is therefore highly uncertain and unpredictable and one or more research and development programs could fail; and (vi) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q filed with the
Nektar Investor Inquiries: |
|
|
(415) 482-5585 |
|
(212) 966-3650 |
Nektar Media Inquiries: |
|
|
(415) 817-2549 |
|
(646) 500-7631 |
SOURCE
News Provided by Acquire Media